Purpose. A case of ocular pythiosis successfully treated with surgery and intraocular and oral minocycline is reported.
Summary.
A 30-year-old man who wore corrective contact lenses traveled to Brazil and Colombia where he swam in salt and fresh waters while wearing contact lenses. He sought treatment at an emergency department after 2 weeks of suffering with a painful corneal ulcer, redness, and loss of vision in his right eye that had been treated at other centers with ophthalmic moxifloxacin for 10 days and with fortified topical antibiotics (amikacin and vancomycin) for 2 days. Examination using a slit lamp revealed a deep central corneal ulcer with surrounding white infiltrate, endothelial plaque, and hypopyon. Due to infection severity, the patient was admitted and received empirical antibiotic therapy and i.v. and topical antifungals. During the first corneal transplantation, the patient's original infection relapsed and was treated with voriconazole and liposomal amphotericin B intraocular injections. A subsequent infection developed, and a second keratoplasty was performed. One month after hospital admission, the patient was diagnosed with ocular pythiosis and therapy with oral minocycline was initiated. After severe infection relapse in the anterior chamber, the patient underwent a third penetrating keratoplasty, where minocycline intraocular injection was administered. After this intervention, complete infection control was achieved, and the patient was discharged 45 days after admission with oral minocycline and 1% cyclosporine and 0.3% ofloxacin eye drops.
Conclusion.
A patient with ocular pythiosis was successfully treated with penetrating keratoplasty and 2 months of treatment with intracameral and oral minocycline.
Keywords: intraocular injection, keratitis, keratoplasty, liposomal amphotericin B, minocycline hydrochloride, pythiosis Am J Health-Syst Pharm. 2017; 74:821-5 P ythium is a genus of oomycete organisms and belongs to the kingdom Chromista (Stramenopila). 1 Phylogenetically, these organisms are more closely related to algae and diatoms than to fungi. Their cell wall is composed of b-glucans and cellulose but lacks ergosterol. These organisms grow in soil and water environments and are plant pathogens. Pythium insidiosum has traditionally been the only species in the genus that infects mammalian hosts. 2 Recently, Pythium aphanidermatum has also been recognized as having the ability to infect mammalian hosts. 3 There are 4 clinical forms of human pythiosis: vascular, ocular, cutaneous/subcutaneous, and disseminated. 1 Risk factors for ocular pythiosis include stagnant water exposure, prior ocular trauma, and contact lens use. Pythiosis has been reported in tropical, subtropical, and temperate countries. It was first documented in 1985 in Thailand, which has the highest percentage of cases. 1 Human pythiosis occurs worldwide but is likely underrecognized and misdiagnosed. 3 Due to a limited knowledge of the disease, diagnosis and treatment are delayed, leading to a poor prognosis, and the majority of patients receive enucleation for infection control. We present the case of a patient with ocular pythiosis who was successfully treated with intraocular minocycline.
Case report
A 30-year-old man who wore corrective contact lenses traveled to Brazil and Colombia where he swam in salt and fresh waters while wearing contact lenses. He sought treatment at an emergency department after 2 weeks of suffering with a painful corneal ulcer, redness, and loss of vision in his right eye that had been treated at other centers with ophthalmic moxifloxacin 5 mg/mL every 2 hours for 10 days and with fortified topical antibiotics hourly (amikacin 20 mg/ mL and vancomycin 25 mg/mL) for 2 days. He suffered from intense ocular pain and intense light photophobia. Examination using a slit lamp revealed a deep central corneal ulcer with surrounding white infiltrate, endothelial plaque, and hypopyon.
Corneal scraping was performed to check for fungi, bacteria, and parasites by direct culture and for viruses of the herpesvirus family by polymerase chain reaction (PCR) analysis, but the results were not definitive.
The patient was admitted to the hospital, and empirical treatment was initiated with the following: i.v. meropenem 1 g every 8 hours, oral doxycycline 100 mg daily, 0.3% ciprofloxacin eye drops; vancomycin 25-mg/mL eye drops; amikacin 20-mg/mL fortified eye drops administered every hour during the day and every 3 hours during the night, medroxyprogesterone acetate 20-mg/mL eye drops every 8 hours, and 1% atropine eye drops administered every 8 hours. After 9 days of treatment, amikacin was changed to ophthalmic ceftazidime 50 mg/mL. A corneal microperforation was surgically sealed with tissue adhesive and a therapeutic contact lens. A second scraping was performed, again yielding no definitive results.
KEY POINTS
• A 30-year-old man who wore corrective contact lenses traveled to Brazil and Colombia where he swam in salt and fresh waters while wearing contact lenses and developed ocular pythiosis.
• The patient was successfully treated with 3 penetrating keratoplasties and intraocular and oral minocycline.
• This article represents the first case of intraocular administration of minocycline described in scientific literature.
The patient's condition worsened 15 days after admission, as he was in severe pain and had a corneal perforation and hypopyon. Penetrating keratoplasty of the right eye was performed, and the cornea was divided in half for pathological and microbiological analyses.
Microbiological analysis confirmed hyphae visualization around the entire corneal sample, suggesting filamentous fungi still to be identified. Since fungal keratitis was suspected, treatment was changed to i.v. voriconazole 360 mg every 12 hours; eye drops containing 5% natamycin, 1% voriconazole, and liposomal amphotericin B 5 mg/mL (1 drop every hour during the day and every 2 hours during the night); and 1 drop of 0.05% chlorhexidine 5 times daily. A few days later, the patient developed an intolerance to the voriconazole eye drop, so it was discontinued and replaced by a 0.5% caspofungin acetate eye drop. Ophthalmic 1% cyclosporine every 6 hours was prescribed, both to avoid the use of corticosteroids during transplantation and to take advantage of its antifungal activity. 4 Because the infection relapsed after transplantation, treatment was enhanced with intraocular injections of intracameral, intrastromal, and intravitreal voriconazole 50 mg/0.1 mL and intracameral and intrastromal liposomal amphotericin B 5 mg/0.1 mL, administered on alternate days.
Although the microbiological test ruled out the presence of Aspergillus species (due to dysmorphic filamentous fungi growth), treatment with oral voriconazole 200 mg every 12 hours was maintained due to low eye penetration of liposomal amphotericin B and infection severity. Oral voriconazole was continued for 5 days.
The infection was still not controlled 25 days after admission, and a second transplantation (of larger diameter to avoid sclera and vitreous involvement) was performed. Again, the patient's cornea was analyzed by the microbiology and pathology departments.
Due to the lack of improvement, systemic treatment was changed to oral posaconazole 200 mg every 6 hours. Intraocular and topical treatments were continued, with the concentration of chlorhexidine reduced to 0.02%. However, 2 days after the second keratoplasty, a white, mushroom-shaped hypopyon was observed at the root of the inferior angle of the anterior chamber, which suggested that the infection possibly spread to the angle or iris tissues.
A month after hospital admission, P. insidiosum was identified as the causative infectious agent by PCR analysis. Thus, the treatment regimen was changed to oral minocycline 100 mg every 12 hours and oral terbinafine 250 mg once daily.
Intraocular liposomal amphotericin B injections and chlorhexidine, liposomal amphotericin B, and caspofungin and natamycin eye drops were maintained until microbiological sensitivity tests confirmed the inefficiency of these agents to inhibit P. insidiosum growth.
Based on the results of a pilot study, photodynamic therapy on the inferior cornea, iris, and camerular angle with i.v. verteporfin injection was applied as adjunctive therapy following retina protocols. 5 The anterior chamber recurrence progressively worsened, and an increase in the intraocular pressure developed 35 days after admission, so a third penetrating keratoplasty expanding the resection to the microscopically infiltrated structures of the anterior chamber was performed. Intracameral minocycline 50-mg/0.1 mL injection was administered during the surgery.
To enhance treatment, an oral potassium iodide 1-mg/mL saturated solution (5 drops at breakfast, lunch, and dinner) was administered in addition to minocycline and terbinafine. Terbinafine and potassium iodide were discontinued after 9 and 5 days of treatment, respectively, due to liver toxicity. Throughout the process, the patient reported intense pain (keratoneuritis) requiring analgesic therapy, prescribed under the supervision of the hospital's department of pain management.
Due to significant clinical improvement, the patient was discharged 45 days after admission with oral minocycline and 1% cyclosporine and 0.3% ofloxacin eye drops.
After 2 months of treatment with oral minocycline, the patient continued to remain free of any sign of infection, and therapy was discontinued. After 1 year of follow-up, the patient had a corrected visual acuity value of 0.5 (20 of 40) without clinical evidence of infection recurrence. He currently uses topical dexamethasone and hypotensive eye drops (brimonidine tartrate 2 mg/mL and timolol maleate 5 mg/mL ophthalmic solution) twice daily.
The pharmacotechnical section of the pharmacy department, part of the multidisciplinary team who treated this patient, advised about the availability of the eye drops and intraocular injections requested. When not commercially available, the pharmacy department assesses the viability of the formulations and prepares them when possible. Ophthalmic preparations of cyclosporine, 6 chlorhexidine, 7 voriconazole, 8 liposomal amphotericin B, 9 and caspofungin 10 were prepared. Also, intraocular injections of voriconazole, liposomal amphotericin B, and minocycline were developed inhouse. Voriconozole 50 mg/0.1 mL was prepared from 1 vial of voriconazole 200 mg using 0.9% sodium chloride injection as the diluent. Liposomal amphotericin B 5 mg/0.1 mL was prepared by reconstituting 1 vial of liposomal amphotericin B with sterile water for injection and further diluting it with 5% dextrose injection. Minocycline 50 mg/0.1 mL was prepared from minocycline pure active ingredient. Minocycline was diluted in 0.9% sodium chloride injection and filtered with a 0.22-mm sterilizing filter. All formulations were prepared using aseptic techniques.
Discussion
This article represents the first case of intraocular administration of minocycline described in scientific literature.
Bacteria, especially Pseudomonas aeruginosa, are the main cause of keratitis in patients with contact lenses. 11 As such, first-line treatment of our patient consisted of antibacterial drugs. Due to the lack of effect of antibacterial drugs, the possibility of a keratitis caused by Acanthamoeba was considered, as it is another pathogen frequently isolated in this infection. Moreover, our patient suffered from characteristic symptoms of Acanthamoeba keratitis, like keratoneuritis, 11 which is why a chlorhexidine eye drop was prescribed.
The hyphae visualization is common in microscopic visualization of fresh corneal scraping samples of ocular pythiosis patients and can lead to a misdiagnosis of fungal keratitis caused by filamentous fungi. 1 This was the reason behind treatment changes to antifungal drugs in our patient. Some of these drugs were prepared in the hospital pharmacy, which required us to study how to prepare those that had never been used before.
The study by Hariprasad et al. 12 was considered when deciding whether an intraocular injection of voriconazole 50 mg/0.1 mL was appropriate for our patient. In this study, 8 of the 40 cases of fungal keratitis and endophthalmitis were treated with intravitreal and intracameral voriconazole 50 mg/0.1 mL along with topical or oral voriconazole. In all cases, the infection was cleared with a favorable adverse-effect profile. On the other hand, Mittal and Mittal 13 presented 5 cases of the successful treatment of fungal keratitis with endothelial exudates with intracameral voriconazole 50 mg/0.1 mL and topical voriconazole. Intracameral amphotericin B 5-10 mg/0.1 mL has been found to effectively treat fungal keratitis and is well tolerated by patients; however, these reports described the use of the deoxycholate form, which is not marketed in Spain. 14, 15 Due to the urgency to start treatment and because the request of a foreign drug would delay its preparation, we prepared the intraocular injection from the liposomal form inhouse. Liposomes have been shown to reduce the number of required administrations and improve the effectiveness and safety profiles of treatments for different ocular pathologies. [16] [17] [18] Kaji et al. 19 evaluated the toxicity and pharmacokinetics of liposomal amphotericin B subconjunctival injection in rabbits and concluded that it had low toxicity and favorable corneal penetration. Tremblay and colleagues 20 compared the intravitreal administration of both liposomal and deoxycholate formulations of amphotericin B in rabbits and found that liposomal amphotericin B was the less toxic of the two formulations.
Pythium species do not have membrane sterols, so a lack of response is expected when treating such infections with azole antifungals. 1, 11 After the identification of P. insidiosum as the causative agent in our patient, oral posaconazole and intraocular voriconazole injections were withdrawn. Treatment with oral minocycline was initiated based on in vitro studies finding that the drug inhibited the growth of P. insidiosum. 21, 22 Growth inhibition was later confirmed with microbiological sensitivity testing. Minocycline bioavailability has been described to be 90%, achieving therapeutic concentrations in the aqueous humor of the uninflamed eye. 23 Oral terbinafine was added to minocycline treatment based on previous reports describing the treatment of ocular pythiosis with 1% topical voriconazole and P. insidiosum vaccine. 24 However, voriconazole therapy was discontinued due to patient intolerance, and the vaccine could not be obtained.
Reported cases of subcutaneous pythiosis responding to terbinafine showed an enhancement of the treatment´s effectiveness by adding potassium iodide. 25 A few days later, both drugs were withdrawn due to liver toxicity, leaving only oral minocycline as systemic therapy.
The Pythium cell wall contains bglucan, so some clinical benefit from caspofungin in pythiosis treatment could be expected due to its inhibitory action of the synthesis of this polysaccharide. However, caspofungin has demonstrated limited fungistatic activity in in vitro and in vivo studies. 26 In our patient, the caspofungin eye drop was continued until microbiological testing confirmed the lack of activity in the inhibition of P. insidiosum growth, consistent with the results found by Lekhanont et al. 11 The final surgery conducted in our patient was the final chance to avoid enucleation, which could have been necessary in the event of a relapse. Once microbiological testing confirmed growth inhibition of P. insidiosum, intracameral minocycline injection was prepared to be administered during this surgery. Moreover, since intraocular minocycline administration has not been previously described, minocycline at a concentration of 50 mg/0.1 mL was established based on an experimental study in which intravitreal tigecycline (a minocycline derivative) 50 mg/0.1 mL was administered to rabbits. 27 Our patient experienced a very satisfactory result, as enucleation was avoided. Since treatment with minocycline was administered at the same time as surgery, we cannot determine whether treatment with minocycline alone or the combination of the drug with surgery was responsible for this treatment success.
Conclusion
